Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer

• DOI: 10.5414/cpp42650
• Publication Date: 2011-03-25T07:58:42Z
• Authors: H. Richly; P. Kupsch; K. Passage; M. Grubert; R.A. Hilger; R. Voigtmann; B. Schwartz; E. Brendel; O. Christensen; C.G. Haase; D. Strumberg
• Keywords: Adult; Male; Niacinamide; Antibiotics, Antineoplastic; Pyridines; Phenylurea Compounds; Benzenesulfonates; Liver Neoplasms; Middle Aged; Sorafenib; Anti-Bacterial Agents; Cholangiocarcinoma; 03 medical and health sciences; 0302 clinical medicine; Doxorubicin; Area Under Curve; Humans; Drug Therapy, Combination; Female; Aged